Rocket Lab USA TodayRKLBRocket Lab USA$22.99 +0.87 (+3.93%) 52-Week Range$3.66▼$33.34Price Target$23.25Add to WatchlistRocket Lab USA NASDAQ: RKLB, a rising force in the aerospace sector, is set to report its first-quarter 2025 earnings on May 8. This earnings release is shaping to be one of the company’s most pivotal, with expectations running high amid growing momentum in government contracts and space systems. The sentiment heading of the report is fairly mixed. While analyst ratings remain broadly bull ...

VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) reports on its year end 2024 and In the year ended December 31, 2024 revenue increased by 37% year over year to $4,785,711 and gross profit increased by 56% to $1,880,306.In the three months ended December 31, 2024 revenue increased by 5% year over year to $1,421,076 and gross profit increased by 18% to $589,930. “Launching and expanding HealthTab™ in North East London has been a mea ...

CareDx (CDNA) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Caroline Corner - Investor RelationsJohn Hanna - President and CEORobert Woodward - Chief Scientific OfficerAbhishek Jain - CFOKeith Kennedy - Chief Operating OfficerVidyun Bais - Equity Research - Vice PresidentBrandon Couillard - Managing DirectorThomas DeBourcy - PrincipalEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants None - AnalystMason Carrico - Research AnalystMatt Stanto ...

CareDx (CDNA) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to today's CareDx First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star one on your telephone keypad. Please note this call may be recorded, and I will be standing by if you should need a ...

Core Viewpoint - Oncocyte Corp. is making significant progress towards initiating a clinical trial for an organ transplant rejection monitoring test kit, which is essential for obtaining regulatory authorization to market the product [1][6]. Company Progress - Oncocyte has completed the clinical trial design and received approval from a central institutional review board (IRB) [2]. - The company expects to include three of the top 10 transplant centers in the U.S. as participants in the clinical trial, representing nearly 10% of the U.S. transplanted organ volume [3]. - Oncocyte estimates that transplant rejection testing generates approximately $500 million in annual revenue in the U.S., with a global addressable market exceeding $1 billion [4]. Market Engagement - The transplant community is enthusiastic about the opportunity to conduct testing in-house, with major transplant centers supporting Oncocyte's efforts [5]. - Oncocyte plans to announce its National Principal Investigator (NPI) soon and will host a conference call to introduce this key opinion leader [5]. Regulatory Pathway - The upcoming clinical trial is the only requirement for FDA authorization of Oncocyte's test kit, which is being pursued through a Class II de novo pathway [6]. - Oncocyte is preparing for its second and final Q-Submission (Q-Sub) meeting with the FDA, following productive discussions in previous meetings [7][8].

More than half say genetic testing for mental health medications could reduce concernsSALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, I ...

登录新浪财经APP 搜索【信披】查看更多考评等级 3、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4、公司全体董事出席董事会会议。 5、立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 6、公司上市时未盈利且尚未实现盈利 □是 √否 公司代码：688135 公司简称：利扬芯片 广东利扬芯片测试股份有限公司2024年年度报告摘要 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本报告第三 节"管理层讨论与分析"之"四、风险因素"相关内容。 7、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 鉴于公司2024年度归属于母公司所有者的净利润为负数，结合公司经营情况及未来资金投入的需求，为 保障公司持续、稳定发展和兼顾公司及全体股东的长远利益，2024 ...

Financial Data and Key Metrics Changes - The company recorded fully diluted EPS of $1.64 and basic EPS of $1.75 for the first quarter, with consolidated net revenues declining by 9% sequentially but increasing by 12% year over year [9][12] - Gross profit was NT$24.9 billion with a gross margin of 16.8%, improving by 0.4 percentage points sequentially and 1.1 percentage points year over year [10][12] - Operating profit was NT$9.7 billion, down NT$1.5 billion sequentially but up NT$2.2 billion year over year, with an operating margin decline of 0.4 percentage points sequentially and an improvement of 0.9 percentage points year over year [11][12] Business Line Data and Key Metrics Changes - In the ATM business, revenues were NT$86.7 billion, down NT$1.7 billion sequentially but up NT$12.8 billion year over year, representing a 2% decline sequentially and a 17% increase annually [15] - The EMS business reported revenues of NT$62.3 billion, declining NT$12.6 billion or 17% sequentially, while increasing NT$2.9 billion or 5% year over year [23] Market Data and Key Metrics Changes - The company noted a potential shallower seasonal dip in EMS business due to customers adjusting order flow patterns, indicating a more stable demand environment [6][23] - The computing segment within the ATM business saw significant growth, particularly driven by stable high demand for AI products, while other segments like handsets were seasonally impacted [19] Company Strategy and Development Direction - The company aims to minimize short-term noise to focus on long-term signals, emphasizing the importance of technological trends and process improvements to maintain competitive advantages [7][8] - The company is committed to increasing its market share in the testing segment, targeting a contribution of 19% to 20% of overall ATM revenue by year-end [21][22] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the second quarter outlook, expecting ATM revenues to grow by 9% to 11% quarter over quarter, while EMS revenues are projected to decline by 10% year over year [30][31] - The management acknowledged the challenges posed by macroeconomic volatility but remains focused on long-term strategic investments [6][8] Other Important Information - The company anticipates a peak in net debt to equity ratio at around 60% in the third quarter of the year, with total unused credit lines amounting to NT$358.4 billion [26] - Capital expenditures for the first quarter totaled NT$892 million, with significant investments planned for machinery and equipment to support future product demands [27][28] Q&A Session Summary Question: AI test market share and CapEx on testing - Management confirmed aggressive investments in the test segment, aiming to increase market share, particularly in AI chip testing, with a target of reaching 20% of ATM revenue by year-end [34][36] Question: U.S. investments and capacity planning - The company is evaluating opportunities for operations in the U.S. to support customer demand, with no specific investment size or timing details available yet [42][44] Question: Market share in AI testing across different products - Management indicated that while they do not have a detailed breakdown of market share by product, they are focused on expanding their test business across all areas, including AI chips [47][49] Question: Impact of tariffs on business - Management stated that the direct exposure to U.S. tariffs is minimal, with less than 10% of EMS shipments going directly to the U.S., and they do not anticipate significant impacts from potential tariffs [93][94] Question: General demand outlook for consumer electronics and automotive - Management noted a gradual recovery in most sectors, with high-end automotive showing better momentum, while lower-end segments are still undergoing inventory corrections [97]

ASE (ASX) Q1 2025 Earnings Call April 30, 2025 02:00 AM ET Speaker0 Thank you for attending our earnings release today. Please refer to our safe harbor notice on Page two. All participants consent to having their voices and questions broadcast via participation in this event. If participants do not consent, please disconnect at this time. I would like to remind everyone that the presentation that follows may contain forward looking statements. These forward looking statements are subject to a high degree of ...

1Q 2025 Financial Results Nasdaq: NEO 1 April 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securit ...